Literature DB >> 19343540

How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses.

Peter M Fayers1, Madeleine T King.   

Abstract

Mesh：

Year:  2009        PMID： 19343540     DOI： 10.1007/s11136-009-9473-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN： 0962-9343            Impact factor:   4.147


× No keyword cloud information.
  12 in total

1.  From star signs to trial guidelines.

Authors:  R Horton
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 2.  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.

Authors:  S T Brookes; E Whitley; T J Peters; P A Mulheran; M Egger; G Davey Smith
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

3.  Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.

Authors:  Sara T Brookes; Elise Whitely; Matthias Egger; George Davey Smith; Paul A Mulheran; Tim J Peters
Journal:  J Clin Epidemiol       Date:  2004-03       Impact factor: 6.437

4.  Misleading subgroup analyses in GISSI.

Authors:  R Peto
Journal:  Am J Cardiol       Date:  1990-09-15       Impact factor: 2.778

5.  Subgroup analyses in randomized clinical trials: statistical and regulatory issues.

Authors:  Jean-Marie Grouin; Maylis Coste; John Lewis
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

Review 6.  Some comments on frequently used multiple endpoint adjustment methods in clinical trials.

Authors:  A J Sankoh; M F Huque; S D Dubey
Journal:  Stat Med       Date:  1997-11-30       Impact factor: 2.373

7.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

8.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

Authors:  S Yusuf; J Wittes; J Probstfield; H A Tyroler
Journal:  JAMA       Date:  1991-07-03       Impact factor: 56.272

9.  Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.

Authors:  Vincent Martin; Roger Cady; Alexander Mauskop; Larry S Seidman; Anthony Rodgers; Carolyn M Hustad; Karen E Ramsey; Franck Skobieranda
Journal:  Headache       Date:  2007-11-13       Impact factor: 5.887

10.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321
View more
  3 in total

1.  Effectiveness of a Web-Based Tailored Intervention With Virtual Assistants Promoting the Acceptability of HPV Vaccination Among Mothers of Invited Girls: Randomized Controlled Trial.

Authors:  Mirjam Pot; Theo Gwm Paulussen; Robert Ac Ruiter; Iris Eekhout; Hester E de Melker; Maxine Ea Spoelstra; Hilde M van Keulen
Journal:  J Med Internet Res       Date:  2017-09-06       Impact factor: 5.428

2.  Prognosis research strategy (PROGRESS) 4: stratified medicine research.

Authors:  Aroon D Hingorani; Daniëlle A van der Windt; Richard D Riley; Keith Abrams; Karel G M Moons; Ewout W Steyerberg; Sara Schroter; Willi Sauerbrei; Douglas G Altman; Harry Hemingway
Journal:  BMJ       Date:  2013-02-05

3.  Creating falseness-How to establish statistical evidence of the untrue.

Authors:  Per Lytsy
Journal:  J Eval Clin Pract       Date:  2017-10       Impact factor: 2.431
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.